Product Description

Influenza is an infection of the respiratory tract caused by influenza virus. It involves a combination of respiratory (cough, sore throat) and constitutional (fever, headache, muscle aches) symptoms. In Children, older adults and people with a range of pre-existing medical conditions influenza infections can lead to serious and even life threatening complications Each year in February the WHO makes a decision on the influenza strains to be included in the following winter's vaccine for the Northern Hemisphere, and in September for the Southern Hemisphere. The WHO Collaborating Centers then release suitable primary seed virus to the manufacturers, like Tianyuan. These primary seed viruses currently comprise three influenza virus strains. In the last step, the components are blended in the correct proportion, and the mixture is filled into syringes or vials of 0.5 ml for adults and 0.*5 ml for children. A syringe or vial contains one dose of trivalent influenza vaccine in the required amount of *5 µg HA per strain for adults and 7.5 ug HA for children. Finally, the vaccine quality is checked and then marketed after approval by the national regulatory authority (SFDA). The product is in compliance with the EU standard. The vaccine is manufactured according to the seasonal WHO recommendation for Northern and Southern Hemisphere. The vaccine's quality level is comparable to internationally available vaccines.